Verici Dx PLC
30 September 2026
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO PURCHASE AND/OR SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN VERICI DX PLC OR ANY OTHER ENTITY IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR THE FACT OF ITS DISTRIBUTION, SHALL FORM THE BASIS OF, OR BE RELIED ON IN CONNECTION WITH ANY INVESTMENT DECISION IN RESPECT OF VERICI DX PLC OR ANY OTHER ENTITY.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION RELATING TO VERICI DX PLC AND ITS SECURITIES FOR THE PURPOSES OF ARTICLE 7 OF THE UK MARKET ABUSE REGULATION, WHICH IS THE UK VERSION OF THE EU MARKET ABUSE REGULATION (596/2014) THAT IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). UPON PUBLICATION OF THIS ANNOUNCEMENT, THE INSIDE INFORMATION CONTAINED HEREIN IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
30 September 2026
Verici Dx plc
(“Verici Dx” or the “Company”)
Proposed Fundraise and Capital Access Window
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces its intention to undertake a proposed equity fundraising with institutional and other investors (the “Proposed Fundraise”).
The Proposed Fundraise is being conducted by Singer Capital Markets and Oberon Investments as joint bookrunners and brokers to the Company.
The Company has elected to utilise AIM's Capital Access Window in connection with the Proposed Fundraise.Accordingly, trading in the Company's Ordinary Shares on AIM will enter a Capital Access Window with effect from 7.30 a.m. on 1 October 2026 and trading will remain paused until a further announcement is made regarding the outcome of the Proposed Fundraise.
The price at which the new Ordinary Shares will be issued and the final number of new Ordinary Shares to be issued pursuant to the Proposed Fundraise will be determined following completion of the bookbuild. The Company will announce the results of the Proposed Fundraise as soon as practicable following completion of the bookbuild.
Proposed Fundraising
As stated at the time, the fundraise in June 2026 has provided the Company with sufficient funding to expand the commercial team, targeted marketing expenditure and to provide further working capital. The Proposed Fundraise will enable the Company to maintain these growth plans. The Board has been greatly encouraged by the support expressed from certain key shareholders to date for the Proposed Fundraise and the Company will update Shareholders with further details shortly.
Interim results
Separately today, the Company has announced its unaudited interim results for the six months ended 30 June 2026 (the "Interim Results”). Investors are encouraged to read the Interim Results in conjunction with this announcement.
Capital Access Window
Following the changes to the AIM Rules for Companies which took effect on 5 August 2026, the Company has elected to utilise the Capital Access Window in connection with the Proposed Fundraise.The new provisions permit AIM companies undertaking an equity fundraising to request a temporary pause in trading while the transaction is being negotiated or marketed.
The Board believes that use of the Capital Access Window is appropriate in connection with the Proposed Fundraise to provide pricing stability while the bookbuild is undertaken and facilitates engagement with a broad range of potential investors.
This announcement does not constitute an offer of securities in any jurisdiction. The Proposed Fundraise, if implemented, will be the subject of further announcements, which will include the material terms and conditions of the Proposed Fundraise.
Enquiries:
|
Verici Dx plc
|
||
|
Sara Barrington, CEO |
Via Walbrook PR |
|
|
Julian Baines, Chairman |
|
|
|
|
|
|
|
Singer Capital Markets (Nominated Adviser & Joint Broker) |
Tel: +44 (0)20 7496 3000 |
|
|
Alex Bond / Russell Cook |
|
|
|
|
|
|
|
Oberon Capital (Joint Broker) |
Tel: +44 (0)20 3179 0500 |
|
|
Mike Seabrook / Adam Pollock |
|
|
|
|
|
|
|
Walbrook PR (Media & Investor Relations) |
Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com |
|
|
Alice Woodings / Rachel Broad |
Mob: +44 (0)7407 804 654 / +44 (0)7747 515 393 |
|
|
|
|
|
|
|
||
About Verici Dx plc www.vericidx.com
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk, to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure, from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.
The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.